ARTICLE | Company News
Lipid Therapeutics, Nestle deal
October 12, 2015 7:00 AM UTC
Lipid granted Nestle’s Nestle Health Science subsidiary exclusive, worldwide rights, excluding Europe and Australia, to develop and commercialize ulcerative colitis candidate LT-02. Nestle will fund a...